Charles Schwab’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-1,567
| Closed | -$50.5K | – | 3604 |
|
|
2022
Q4 | $50.5K | Hold |
1,567
| – | – | ﹤0.01% | 3356 |
|
|
2022
Q3 | $66K | Sell |
1,567
-4,396
| -74% | -$185K | ﹤0.01% | 3271 |
|
|
2022
Q2 | $252K | Sell |
5,963
-4,287
| -42% | -$181K | ﹤0.01% | 3213 |
|
|
2022
Q1 | $695K | Buy |
10,250
+167
| +2% | +$11.3K | ﹤0.01% | 2990 |
|
|
2021
Q4 | $1.23M | Buy |
10,083
+349
| +4% | +$42.4K | ﹤0.01% | 2836 |
|
|
2021
Q3 | $1.37M | Buy |
9,734
+125
| +1% | +$17.6K | ﹤0.01% | 2778 |
|
|
2021
Q2 | $2.64M | Buy |
9,609
+1,089
| +13% | +$299K | ﹤0.01% | 2619 |
|
|
2021
Q1 | $1.82M | Buy |
8,520
+1,892
| +29% | +$405K | ﹤0.01% | 2689 |
|
|
2020
Q4 | $1.6M | Sell |
6,628
-586
| -8% | -$142K | ﹤0.01% | 2653 |
|
|
2020
Q3 | $761K | Buy |
7,214
+3,544
| +97% | +$374K | ﹤0.01% | 2745 |
|
|
2020
Q2 | $360K | Buy |
3,670
+258
| +8% | +$25.3K | ﹤0.01% | 2963 |
|
|
2020
Q1 | $257K | Buy |
3,412
+51
| +2% | +$3.84K | ﹤0.01% | 2937 |
|
|
2019
Q4 | $273K | Sell |
3,361
-442
| -12% | -$35.9K | ﹤0.01% | 2994 |
|
|
2019
Q3 | $465K | Buy |
3,803
+1,598
| +72% | +$195K | ﹤0.01% | 2828 |
|
|
2019
Q2 | $397K | Buy |
2,205
+154
| +8% | +$27.7K | ﹤0.01% | 2916 |
|
|
2019
Q1 | $329K | Buy |
2,051
+24
| +1% | +$3.85K | ﹤0.01% | 2914 |
|
|
2018
Q4 | $528K | Buy |
2,027
+829
| +69% | +$216K | ﹤0.01% | 2744 |
|
|
2018
Q3 | $292K | Buy |
1,198
+69
| +6% | +$16.8K | ﹤0.01% | 3010 |
|
|
2018
Q2 | $267K | Buy |
+1,129
| New | +$267K | ﹤0.01% | 3010 |
|